{"denoms":[{"counts":[{"groupId":"BG000","value":"398"},{"groupId":"BG001","value":"397"},{"groupId":"BG002","value":"795"}],"units":"Participants"}],"groups":[{"description":"Patients administered 40 milligram (mg) film-coated tablet once daily orally for the first 28-day treatment course. Dose escalation to 50 mg once daily was allowed at the beginning of the second 28-day treatment course, if patients met specified safety and compliance criteria. Dose reduction to 40 mg/day (if applicable), 30 mg/day, or 20 mg/day, was required in the presence of known drug-related adverse events.","id":"BG000","title":"Afatinib"},{"description":"Patients administered 150 mg film-coated tablet once daily orally, with dose reduction to 100 mg/day or 50 mg/day in the presence of known drug-related adverse events.","id":"BG001","title":"Erlotinib"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.39","value":"64.9"},{"groupId":"BG001","spread":"8.98","value":"63.4"},{"groupId":"BG002","spread":"8.72","value":"64.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"Randomised set","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"66"},{"groupId":"BG002","value":"129"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"335"},{"groupId":"BG001","value":"331"},{"groupId":"BG002","value":"666"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Randomised set","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"97"},{"groupId":"BG001","value":"94"},{"groupId":"BG002","value":"191"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"15"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"288"},{"groupId":"BG001","value":"291"},{"groupId":"BG002","value":"579"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"6"}],"title":"Unknown or Not Reported"}]}],"description":"Ethnicity was not captured in this trial.","paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Randomised set","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"Randomized Set (RS): All patients who were randomized, regardless of whether they received investigational treatment."}